Dry Springs Pharmacy – FDA Warning Letter, Apr 1, 2026

On April 1, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dry Springs Pharmacy, a Hong Kong-based company, following an investigation of its website. The FDA found that the pharmacy was distributing unapproved and misbranded drugs into U.S. interstate commerce, specifically targeting high-risk medications including opioids (OxyNorm), benzodiazepines (Yellow Xanax), and Schedule II stimulants (Adderall). These actions violate several sections of the Federal Food, Drug, and Cosmetic Act. The primary issues identified involve the sale of prescription-only medications without requiring a valid prescription from a licensed practitioner. The FDA noted that these drugs carry significant risks of addiction, overdose, and death, and that selling them without proper medical oversight and mandatory "black box" warnings poses a severe threat to public health. Additionally, because the drugs are not FDA-approved, they lack the necessary guarantees of safety, purity, and effectiveness. The pharmacy is required to immediately stop offering these unapproved and misbranded products to U.S. consumers. Dry Springs Pharmacy must provide a written response to the FDA within 15 working days detailing the specific steps taken to correct these violations and ensure future compliance. The agency warned that failure to take corrective action could result in legal measures, such as the seizure of products or injunctions, and noted that international shipments may be detained at U.S. borders.